1867 results about "Tumor therapy" patented technology

A federated distributed computational system enables secure biological data analysis and genomic medicine with enhanced oncological therapy capabilities. The system implements patient-specific tumor-on-a-chip analysis through microfluidic control systems and cellular heterogeneity preservation, while integrating fluorescence-enhanced diagnostics using CRISPR-LNP targeting and robotic surgical navigation. The architecture coordinates spatiotemporal analysis of gene therapy delivery through molecular imaging and immune response tracking, and implements bridge RNA integration with multi-target synchronization. Treatment selection is optimized through multi-criteria scoring and patient-specific simulation modeling. Each federated node contains a local processing unit for biological data analysis, privacy preservation protocols, and a hierarchical knowledge graph structure. The system implements cross-species genetic analysis, environmental response modeling, and multi-scale tensor-based data integration, enabling research institutions to collaborate on complex, large-scale biological analyses while maintaining strict data privacy controls.

A federated distributed computational system enables secure oncological therapy optimization through robotic integration. The system establishes a distributed graph architecture with secure communication channels connecting computational nodes, implementing encryption protocols for cross-institutional data exchange. Each node contains processing capabilities for fluorescence-guided imaging, uncertainty quantification, and expert knowledge integration while maintaining hierarchical knowledge graphs of oncological biomarkers, interventions, and outcomes. The system coordinates domain-specific knowledge through token-space communication and implements an advanced robotic integration system for surgical interventions using spatiotemporal tumor mapping, multi-modal fluorescence imaging, surgical robot coordination, and space-time stabilized mesh management. Key capabilities include wavelength-specific multi-modal fluorescence detection, combined epistemic and aleatoric uncertainty estimation, tensor-based data integration with adaptive dimensionality control, and light cone search for adaptive treatment optimization—all while maintaining strict privacy controls.

A federated distributed computational system enables secure biological data analysis and genomic medicine through hybrid simulation capabilities. The system implements a hybrid simulation orchestrator that coordinates classical numerical simulations with machine learning models for biological system analysis, while maintaining secure cross-institutional data exchange. The architecture coordinates multi-scale spatiotemporal synchronization across computational nodes, with each node containing local processing capabilities for biological data analysis and privacy preservation protocols. The system implements cellular machinery assembly analysis, real-time patient data integration, and multi-modal image integration with spatiotemporal health data annotation. Through a distributed graph architecture, the system enables cross-species genetic analysis, environmental response modeling, and multi-scale tensor-based data integration with adaptive dimensionality control. The system implements real-time therapeutic response prediction through multi-modal data analysis, enabling research institutions to collaborate on complex biological analyses while maintaining strict data privacy controls.

The present invention belongs to the technical field of medicinal chemistry, and particularly relates to a pyrimidine macrocyclic compound. The compound has a good inhibitory effect on KRAS mutations, has a good inhibitory effect on the G12V mutation and other types of mutations of the KRAS gene, can be used as a general KRAS inhibitor, and can be used for the treatment of tumors driven by KRASG12V and other types of gene mutations.

The invention relates to the technical field of medical image processing and tumor treatment, and provides a tumor image boundary identification method and system fused with a fluorescence boundary, and the method comprises the steps: collecting a tumor dynamic fluorescence image sequence and breathing waveform data through a fluorescence imaging device; performing multi-scale noise suppression processing on the image sequence to generate a preprocessed image without artifacts; extracting fluorescence intensity distribution characteristics through a multi-layer characteristic weighted fusion network and generating an intensity distribution matrix; constructing a motion compensation model according to the breathing waveform data, and correcting the boundary displacement of the intensity distribution matrix; fusing the corrected fluorescence features and the tumor tissue texture features to generate an initial tumor boundary contour; iterative topological optimization is carried out on the initial boundary, and boundary discontinuity is eliminated; and mapping the optimized boundary to a space coordinate system of the laser treatment equipment, generating a boundary mapping model and updating the boundary mapping model in real time. The precision and safety of laser treatment can be improved, and damage to normal tissue is reduced.

The invention relates to the technical field of tumor treatment, in particular to an intelligent decision-making system for tumor precise targeted medication based on individual mutation information, which comprises a data processing layer, a variation annotation and function prediction layer, a knowledge base integration layer and a scheme decision-making engine and report visualization module. According to the intelligent decision-making system for tumor precise targeted medication based on individual mutation information, a rule engine and a prediction model are combined, dynamic priority ranking is output, multi-model fusion decision making is achieved, and clinical scene deep adaptation is achieved by predicting primary and secondary drug resistance, calculating liver and kidney function adjusting dosage and generating a combined medication time sequence scheme; through an individualized drug delivery scheme, combination drug use optimization is achieved, a visual clinical report is generated, clinical executable operation is further strengthened, and through algorithm quantification, a dynamic knowledge graph, AI auxiliary decision making and a clinical operation closed loop, the next-generation technical research direction of a tumor precise drug use system can be represented.

The invention discloses a ginsenoside liposome. The ginsenoside liposome comprises ginsenoside, phospholipid and a surfactant, and the ginsenoside comprises protopanoxadiol or / and protopanaxatriol. The invention also discloses a preparation method of the ginsenoside liposome and application of the ginsenoside liposome in preparation of medicines, cosmetics or skin care products. According to the invention, the final desugared product of ginsenoside with the effect of treating skin toxicity reaction is prepared into the liposome, so that the membrane permeation and absorption capabilities of ginsenoside are greatly improved, the skin toxicity caused by tumor treatment can be quickly and effectively relieved, and the drug effect can be played for a long time; the invention provides a new method for treating skin toxic reaction caused by tumor treatment, and makes up for the requirements which cannot be met by the existing treatment means.

The invention discloses a digital intelligent tumor prevention and treatment management platform and management method, and relates to the technical field of intelligent medical treatment, and the method comprises the steps: collecting the multi-modal data of a patient in real time, carrying out the standardized cleaning and space-time alignment processing, and generating a space-time tagging data set; inputting the multi-modal joint feature representation into an anti-fact inference engine, simulating potential effects under intervention of different treatment schemes, calculating individual processing effects, and generating an anti-fact rehabilitation suggestion set; according to the anti-fact rehabilitation suggestion set, a dynamic causal enhancement decision model is constructed, real-time physiological data feedback of the patient is continuously received through a near-end strategy optimization algorithm, and a treatment scheme is dynamically adjusted. According to the method, through multi-modal data space-time alignment and feature fusion, in combination with a tumor biological mechanism and a machine learning algorithm, the accuracy and clinical credibility of individualized tumor treatment scheme recommendation are remarkably improved.

According to the precise diagnosis and treatment integrated platform and method based on the coupling model, the cavitation effect is predicted through numerical simulation, negative feedback adjustment is conducted on microbubble mediated ultrasonic treatment, and precise control over the microbubble mediated ultrasonic treatment is achieved. Acoustic parameters are adjusted in real time, it can be ensured that treatment focuses on a lesion area, damage to surrounding healthy tissue is reduced, and therefore the accuracy and safety of treatment are improved. The platform integrates cavitation detection and an acoustic feedback mechanism, the microbubble cavitation effect can be monitored in real time, and treatment parameters can be automatically adjusted. Negative feedback closed-loop control can ensure a stable cavitation state, tissue damage caused by excessive cavitation is effectively avoided, and the stability and reliability of treatment are improved. The platform simplifies the operation process of controlling acoustic parameters. A doctor can complete the whole process from treatment to monitoring on the same operation interface through the integrated platform, and convenience and efficiency of clinical operation are improved. The platform is not only suitable for tumor treatment, ablation and drug delivery, but also can be applied to multiple treatment fields such as vascular diseases and neuromodulation, and has wide clinical application prospects and market potential.

The invention discloses a multi-metal borate nano-particle as well as a preparation method and application thereof. The preparation method comprises the following steps: in the presence of small molecules with alkyl chains, performing high-temperature thermal decomposition on an organic metal compound or a metal salt compound precursor and organic borate in a solvent, and then centrifuging, modifying, performing ultrafiltration, dialyzing and purifying to obtain the multi-metal borate nanoparticles. The preparation method disclosed by the invention has the characteristics of mildness, high efficiency and strong controllability. The multi-metal borate nanoparticles prepared by the preparation method disclosed by the invention have the advantages of monodisperse size, relatively high magnetic property and good biocompatibility. Therefore, the prepared multi-metal borate nanoparticles not only have multi-modal imaging functions such as magnetic resonance imaging, near-infrared two-region imaging, nuclear medicine imaging and magnetic particle imaging, but also can be used for various treatment means such as magnetocaloric therapy and boron neutron capture therapy; potential advantages are realized in biomedical applications such as magnetic targeting tumor treatment and imaging contrast agents, and high practical values are realized.

The invention provides a tumor treatment effect prediction method based on multi-modal data, and relates to the field of medical artificial intelligence. The method comprises the following steps: collecting magnetic resonance image data, histopathological section images and clinical baseline data of a tumor patient and a treatment response evaluation record after neoadjuvant chemotherapy; the collected image information is preprocessed; feature extraction is carried out based on the preprocessed image information; screening a feature subset with the highest prediction value from the extracted features; constructing a radiopathomics fusion model by using the feature subset with the highest prediction value; evaluating the radiopathomics fusion model; and predicting the tumor treatment effect by using the evaluated radiopathomics fusion model. The problems that an existing tumor neoadjuvant chemotherapy (NACT) curative effect prediction method is low in accuracy, poor in generalization ability, lack of multi-modal data fusion and insufficient in model interpretability are solved.

The invention discloses a cat serum albumin combined nano antibody as well as a preparation method and application thereof, and relates to the technical field of nano antibody engineering. Wherein the amino acid sequence of the cat serum albumin binding nano antibody Nb1 is shown as SEQ.ID NO.1, and the nano antibody Nb1 not only has higher affinity to cat serum albumin, but also has better binding activity to mouse serum albumin; the polypeptide can be widely applied to the aspects of drug half-life period enhancement, tumor targeted therapy and imaging, immunodetection or diagnosis, recombinant albumin purification or enrichment and the like in the pet treatment process.

The invention discloses a dual-mechanism antibacterial photosensitizer as well as a preparation method and application thereof, and relates to the technical field of biomedical photoelectric functional materials. The invention relates to a triphenylamine derivative, which can realize fluorescence imaging of bacterial or fungal infection by utilizing fluorescence characteristics, can generate active oxygen under illumination to play a photodynamic therapy role, is suitable for preparing photodynamic therapy preparations and developing antibacterial materials, and can also be applied to the fields of environment and public health and tumor treatment. The problems that an existing photosensitizer is insufficient in broad spectrum, different in fungus drug resistance mechanism, limited in single treatment effect and the like can be effectively solved, and the photosensitizer has wide application prospects.

The invention belongs to the technical field of biological medicine, and particularly relates to a manganese-doped zeolite imidazole framework and application thereof in tumor radiotherapy. According to the present invention, the new use of the manganese-doped zeolite imidazole framework as the tumor radiosensitizer is found, Mn-ZIF-8 has ray responsiveness, can continuously release Mn < 2 + > ions under X-ray irradiation, and can enhance the activation of a cGAS-STING signal channel so as to promote DCs maturation and antigen presentation, and enhance the T cell mediated immune response, such that the tumor treatment effect is enhanced. Furthermore, the invention provides the Mn-ZIF-8 microneedle, the microneedle has the characteristics of rapid dissolution and controlled release, ensures accurate delivery and continuous action of drugs at tumor sites, reduces systemic toxicity, and can significantly amplify local and systemic immune effects caused by radiotherapy and improve the therapeutic effect when used in combination with an immune checkpoint inhibitor.

The invention discloses an OTX-015 (Ox-015) loaded cascaded responsive nano particle and a preparation method thereof. The nanoparticle has a three-layer core-shell structure, wherein the innermost layer is a cross-linked nanoparticle of chitosan and paclitaxel; the middle layer is a polydopamine layer loaded with a bromodomain inhibitor OTX-015; the outermost layer is a gelatin layer grafted with babali; wherein the cross-linked substance of the chitosan and the paclitaxel is a cross-linked substance containing a disulfide bond. The invention also provides a preparation method of the cascade responsive nano-particle and application of the cascade responsive nano-particle in preparation of an antitumor drug targeted delivery system. The nanoparticle provided by the invention improves the tumor microenvironment while activating in-vivo autoimmunity, and kills tumor cells by using photothermal therapy assisted chemotherapy drugs, so that the synergistic effect of chemotherapy / photothermal therapy / immunotherapy is realized, and a new idea is provided for clinical tumor treatment.

Provided is a recombinant human serum albumin-collagen binding domain (CBD) fusion protein for tumor-specific targeting matrix and its use in specific targeted treatment of a solid tumor. HSA and the CBD generate gene fusion in the form of different molecular structures, and can be expressed in a constructed recombinant engineered host. A pharmaceutical recombinant fusion protein is obtained through large-scale fermentation. The recombinant fusion protein shows tumor-specific targeting of solid tumors and can be used as a starting material of a broad-spectrum matrix carrier. The recombinant fusion protein is coupled with any tumor treatment drug, small-molecule compound, or cytotoxic protein to form an innovative pharmaceutical composition. The pharmaceutical composition of the recombinant fusion protein is also long-acting, can prolong a half-life of the conjugate drug in vivo, and has a significantly better clinical curative efficacy on anti-tumor than that of a monomer drug.

The present invention relates to the field of tumor treatment and immunology biology. Provided are a pharmaceutical combination containing an anti-PD-1-anti-VEGFA bispecific antibody, and the use thereof. Specifically, the pharmaceutical combination comprises at least one bispecific antibody and at least one PARP inhibitor, wherein the bispecific antibody comprises a first protein functional region for targeting PD-1 and a second protein functional region for targeting VEGFA; and according to the EU numbering system, the heavy chain constant region of an immunoglobulin contained in the bispecific antibody is mutated at two sites, i.e. site 234 and site 235, and after mutation, the affinity constant of the bispecific antibody to FcγRI, FcγRIIa, FcγRIIIa and / or C1q is reduced compared with the affinity constant of the bispecific antibody thereto before mutation. The combined administration of the PARPi and the bispecific antibody has a significantly better therapeutic effect on tumors than the individual use of the PARPi or the bispecific antibody; and the present invention has good application prospects.

The invention relates to a strontium peroxide nano-material, which is characterized in that a strontium source, alkali and hydrogen peroxide are used as raw materials, a mixed solution of an organic solvent and water is used as a reaction solvent, the strontium peroxide nano-material is prepared under a template or template-free condition, and the strontium peroxide nano-material can quickly react with water to generate hydroxyl, hydrogen peroxide and oxygen, hydrogen peroxide can achieve a tumor cell killing effect, hydroxyl can neutralize an acidic tumor microenvironment and alkalify tumor cells, and oxygen can relieve a hypoxic tumor microenvironment. In addition, the strontium peroxide nano material can induce macrophages to be polarized to an anti-tumor M1 type by regulating and controlling glycometabolism of the macrophages, and remodeling an intra-tumor lactic acid metabolism crosstalk mode. The strontium peroxide nano-material or the modified material and the preparation thereof can be directly injected into a tumor or near the tumor under ultrasonic guidance to realize in-situ treatment, or can be delivered to a tumor supply blood vessel through a catheter to realize embolism treatment, so that the strontium peroxide nano-material or the modified material and the preparation thereof have a certain application prospect in the field of tumor treatment.

The invention provides an application of licorice extracts GL, 18beta-GA and DG in tumor treatment, in particular to an application in treatment of uveal melanoma (UM).

The invention discloses a metal polyphenol network modified drug-loaded radioactive microsphere as well as a preparation method and application thereof, radionuclides are labeled on different microspheres by a precipitation method or an adsorption method, and the metal polyphenol network is modified on the surface of the radioactive microsphere to improve the nuclide labeling stability and the synchronous drug loading capability of the radioactive microsphere. Subsequently, medicine molecules can be adsorbed to the modified radioactive microspheres to obtain the metal polyphenol network modified medicine-carrying radioactive microspheres. The metal polyphenol network modified drug-loaded radioactive microspheres prepared by the invention can solve the problems of radionuclide non-target shedding and DNA damage repair caused by nuclear drugs, avoid secondary drug administration, ensure that drugs directly and accurately reach tumor targets, and improve the drug delivery efficiency. And the selective internal irradiation therapy based on radioactive microsphere mediation is further promoted to play a more effective tumor treatment effect.

The invention provides an organic molecule cytoplasm delivery carrier as well as a preparation method and application thereof, the compound for cytoplasm delivery has the characteristic of fat-soluble aggregation, and can form electrostatic adsorption with small molecule protein goods such as RNase A (13.7 KDa), Trypsin (24KDa) and Saporin (32.8 KDa), medium molecule protein goods such as HRP (40KDa) and macromolecular protein goods such as beta-Gal (430KDa), so that the compound for cytoplasm delivery can be used for preparing a lipid-soluble protein carrier. And furthermore, transmembrane transportation is formed through the strong fat solubility property, so that the protection and intracellular delivery of carried protein molecules are realized. According to the delivery mechanism, cargo molecules can quickly penetrate through cell membranes, and carried protein molecules can enter cytoplasm to exert functions without release operation. Development of the organic molecule cytoplasm delivery carrier is expected to assist potential protein therapies with low bioavailability and off-target toxicity to complete clinical transformation, which is crucial to tumor therapy, gene therapy and the like requiring precise local administration.

The invention discloses a preparation method of polygonatum-sibiricum-sourced exosome-like nano-vesicles and application of the nano-vesicles in antitumor drugs, and relates to the technical field of biological medicines. The preparation method comprises the following steps: crushing fresh rhizoma polygonati slices, filtering and collecting to obtain a first filtrate; carrying out gradient centrifugation treatment on the first filtrate to obtain supernate; carrying out first membrane filtration treatment on the supernate to obtain second filtrate with the particle size of less than 450 nm; centrifuging the second filtrate to obtain a precipitate, and resuspending the precipitate with a PBS buffer solution to obtain a rhizoma polygonati exosome crude extract; and performing secondary membrane filtration treatment on the rhizoma polygonati exosome crude extract to obtain a third filtrate with the particle size of less than 220nm, thereby obtaining the rhizoma polygonati-derived exosome-like nano-vesicles. The polygonatum-sibiricum-sourced exosome-like nano-vesicle has remarkable inhibitory activity on tumors, provides a new strategy and means for tumor treatment, and has important scientific value and clinical application potential.

Disclosed are methods of augmenting efficacy of oncology therapies by providing reprogrammed cells such as personalized regenerative cells that modulate the tumor microenvironment. In one embodiment, somatic cells are dedifferentiated into OCT-4 expressing cells and endowed with tumor homing properties through culture or gene engineering. Once a stable population of tumor homing cells is established, such cells are made to express immune stimulating agents constitutively, or selectively upon entering the cancer microenvironment. Selective expression of immune stimulatory agents can be induced by exposure to hypoxia, acidosis, immune suppressive signaling or inflammatory signaling.

The invention provides application of TRMT61A and its inhibitor tetramethylthiuram disulfide in tumor immunotherapy, and relates to the technical field of biological medicine, clinical research proves that RNA m1A methyltransferase TRMT61A is highly expressed in tumor tissues and is related to poor prognosis of tumor patients, and can be used as one of tumor therapy targets. Meanwhile, high expression of the TRMT61A is related to poor prognosis of a tumor patient receiving anti-PD-1 immunotherapy, and after anti-PD-1 antibody immunotherapy is carried out on the patient with low TRMT61A expression level in the tumor of the patient, pathological complete relief is easier. Tetramethylthiuram disulfide inhibits TRMT61A, inhibits m1A modification regulation of TRMT61A on PD-L1 mRNA, increases PD-L1 protein expression, and is combined with a PD-1 antibody drug to significantly enhance the immunotherapy effect of the anti-PD-1 immune checkpoint drug in treating malignant tumors.

The invention provides an electrode slice temperature detection method and an alternating current signal application method for tumor treatment. According to the method, a direct-current electric signal is transmitted to a dual-purpose signal line of an electrode plate, and grounding wires are sequentially conducted in a time-sharing manner, so that temperature detection signals detected by temperature sensors are acquired line by line. The dual-purpose signal wire and the grounding wire of the electrode plate are controlled in a combined mode to collect the temperature detection signals detected by the temperature sensors, the temperature can be comprehensively and accurately monitored, the number of conductive traces is effectively reduced, and efficient and accurate electrode plate control is achieved. In addition, alternating current electric signals applied to the dielectric elements of the electrode plate can be controlled or adjusted according to the collected temperature detection signals, low-temperature scalding can be avoided, and the use safety of the electrode plate is improved.

The invention belongs to the technical field of biological medicines, and particularly relates to an iron-based nano material, a preparation method and application of the iron-based nano material in preparation of medicines for treating breast cancer. The iron-based nano material is formed by loading a ferroptosis inducer on a nano carrier; the nano carrier is an iron-based metal organic framework material Fe-MOF (Metal Organic Framework). A product FEH for treating breast cancer is obtained based on coupling of the iron-based nano-material provided by the invention with a targeted drug such as trastuzumab. The FEH provides a new method for developing a nano platform with an antibody function, and realizes a treatment strategy of trastuzumab and ferroptosis combined anti-tumor. As a safe and effective tumor treatment strategy, the EFH has huge clinical transformation potential.

The invention discloses poplar and phellinus igniarius polysaccharide SVP-1 as well as a preparation method and application thereof, and belongs to the field of biological medicines. The poplar phellinus igniarius polysaccharide SVP-1 provided by the invention has remarkable anti-tumor activity, and can effectively inhibit proliferation, invasion and migration of tumor cells so as to block malignant progression of tumors. The structure is clear, the preparation method is controllable, the stability and biological activity of polysaccharide components are ensured, and a reliable basis is provided for development of antitumor drugs. When the traditional Chinese medicine composition is used together with radiotherapy and chemotherapy medicines, a synergistic effect can be achieved, the sensitivity of tumors to treatment can be improved, the toxic and side effects of radiotherapy and chemotherapy can be relieved, and the effects of reducing toxicity and increasing efficiency are achieved. According to the combined treatment strategy, the curative effect of the existing tumor therapy can be remarkably improved, meanwhile, adverse reactions are reduced, and a new optimization scheme is provided for clinical tumor treatment.

The invention discloses an anti-CLDN6 nano antibody and related application thereof, and relates to the field of antibodies. The invention provides an anti-CLDN6 nano antibody, which comprises HCDR1, HCDR2 and HCDR3 in a heavy chain variable region of which the amino acid sequence is as shown in SEQ ID NO: 4, the nano antibody has excellent antigen binding activity, high specificity and good affinity, has relatively strong killing activity on cells with high expression of CLDN6, and can be used for preparing anti-CLDN6 drugs. The requirements of CLDN6 positive tumor immunotherapy on efficient, specific and high-penetrability antibody molecules are met, and a new strategy and means are provided for tumor therapy.

The invention discloses a specific cell targeted hybrid nano-delivery carrier and a preparation method and application thereof, and aims to solve the problems of insufficient specificity, off-target risk, low delivery efficiency and the like of an existing drug delivery system. And a bionic hybrid nano delivery platform with a natural targeting function and high drug loading capacity is constructed. The vector retains key receptor molecules and signal markers on a source cell membrane, and can actively identify and target corresponding cells; meanwhile, due to the introduction of the lipidosome, the yield and stability of the material are remarkably improved, and the immune clearance rate is reduced. Experimental results show that the nano-carrier shows good targeting and biocompatibility in various disease models, and has wide clinical application prospects in the aspects of tumor treatment, tissue repair, inflammation control, targeted imaging and the like.

The invention discloses an application of the number of neutrophils in predicting the curative effect of oncolytic viruses in treating tumors. In the application, the neutrophile granulocyte number level in the blood of a tumor patient is closely associated with the tumor treatment effect, and the applicable tumor syndromes are common, including melanoma, colorectal cancer, esophageal cancer, head and neck tumors, gastric cancer, biliary tract system tumors, sarcoma and other tumors. In the application, the critical value of the number of neutrophils for predicting the tumor treatment effect is 2 * 10 < 9 >-5.5 * 10 < 9 > / L, and the most preferable critical value is 4.0 * 10 < 9 > / L; the curative effect of OH2 single-drug treatment on tumor patients with the neutrophil number level below a critical value is better than that of tumor patients with the neutrophil number level above the critical value.